Novel feedback inhibition of surface antigen synthesis by mammalian target of rapamycin (mTOR) signal and its implication for hepatitis B virus tumorigenesis and therapy

Authors

  • Chiao-Fang Teng,

    1. Institute of Basic Medical Sciences, National Cheng Kung University College of Medicine and Hospital, Tainan, Taiwan
    Search for more papers by this author
  • Han-Chieh Wu,

    1. National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Tainan, Taiwan
    Search for more papers by this author
  • Hung-Wen Tsai,

    1. Department of Pathology, National Cheng Kung University College of Medicine and Hospital, Tainan, Taiwan
    Search for more papers by this author
  • Her-Shyong Shiah,

    1. National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan
    Search for more papers by this author
  • Wenya Huang,

    1. Department of Medical Laboratory Science and Biotechnology, National Cheng Kung University College of Medicine and Hospital, Tainan, Taiwan
    Search for more papers by this author
  • Ih-Jen Su

    Corresponding author
    1. Institute of Basic Medical Sciences, National Cheng Kung University College of Medicine and Hospital, Tainan, Taiwan
    2. National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Tainan, Taiwan
    3. Department of Pathology, National Cheng Kung University College of Medicine and Hospital, Tainan, Taiwan
    • National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, 367 Sheng-Li Road, Tainan 704, Taiwan
    Search for more papers by this author
    • fax: 886-6-208-3466


  • Potential conflict of interest: Nothing to report.

Abstract

Ground glass hepatocytes (GGHs) harboring hepatitis B virus (HBV) pre-S mutants have been recognized as precursor lesions of hepatocellular carcinoma (HCC). Previously, we observed the activation of mammalian target of rapamycin (mTOR) in GGHs and HCCs, together with a decreased expression of HBV surface antigen (HBsAg) in HCC tissues. It is, therefore, hypothesized that the activation of mTOR during HBV tumorigenesis may potentially down-regulate HBsAg expression. In this study, we verified an inverse relationship between the expression of HBsAg and phosphorylated mTOR (p-mTOR) in 13 of 20 paired nontumorous liver and HCC tissues. In vitro, wild-type or mutant pre-S proteins could activate mTOR in the HuH-7 cell line. Interestingly, the up-regulated mTOR, in turn, suppressed HBsAg synthesis at the transcriptional level via the transcription factor, Yin Yang 1 (YY1), which bound to nucleotide 2812-2816 of the pre-S1 promoter. This inhibitory effect by the mTOR signal could be abolished by the knockdown of histone deacetylase 1 (HDAC1). Furthermore, YY1 was physically associated with HDAC1 in a manner dependent on mTOR activation. Collectively, pre-S protein-induced mTOR activation may recruit the YY1-HDAC1 complex to feedback suppress transcription from the pre-S1 promoter. Conclusion: The activation of mTOR signal in GGHs may feedback suppress HBsAg synthesis during HBV tumorigenesis and explain the observed decrease or absence of HBsAg in HCC tissues. Therapy using mTOR inhibitors for HCCs may potentially activate HBV replication in patients with chronic HBV infection. (HEPATOLOGY 2011 )

Ancillary